

Increased Activity and Emerging Patterns in Securities Litigation Against Life Sciences Companies

July 19, 2017 | Client Update

We

[previously outlined](#)

the growing threat of securities class action lawsuits against life sciences companies and the importance of the United States Supreme Court's decision in *Omnicare*. In that case, the Supreme Court addressed liability under the federal securities laws for statements of opinion, and gave important guidance for defending actions based on such statements. Since our last report, securities litigation against life sciences companies has continued to be highly active. Core filings (i.e., non-M&A filings) against life sciences and healthcare companies more than doubled between the first quarter of 2016 and the first quarter of 2017: from 15 in Q1 2016 to 36 in Q1 2017. There is no indication that this trend is likely to abate soon.

If you have any questions regarding the matters covered in this publication, please reach out to any of the lawyers listed below or your usual Davis Polk contact.

Bruce K. Dallas

+1 650 752 2022
bruce.dallas@davispolk.com

Alan F. Denenberg

+1 650 752 2004
alan.denenberg@davispolk.com

Michael S. Flynn

+1 212 450 4766
michael.flynn@davispolk.com

Deanna L. Kirkpatrick

+1 212 450 4135
deanna.kirkpatrick@davispolk.com

Edmund Polubinski

+1 212 450 4695
edmund.polubinski@davispolk.com

Neal Potischman

+1 650 752 2021
neal.potischman@davispolk.com

James P. Rouhandeh

+1 212 450 4835
rouhandeh@davispolk.com

Richard D. Truesdell, Jr.

+1 212 450 4674
richard.truesdell@davispolk.com

Brian S. Weinstein

+1 212 450 4972
brian.weinstein@davispolk.com

This communication, which we believe may be of interest to our clients and friends of the firm, is for general information only. It is not a full analysis of the matters presented and should not be relied upon as legal advice. This may be considered attorney advertising in some jurisdictions. Please refer to the firm's privacy notice for further details.

Related materials

[2017_07_19_increased_activity_emerging_patterns_securities_litigation_against_life_sciences_companies.pdf](#)